Global In Vitro Fertilization (IVF) Market Report: 2016 Edition
In Vitro Fertilization (IVF) is a process of fertilizing the egg outside the body. It is helpful for those couples who are suffering from infertility and hence are not able to conceive a child but want to have a family. There has been an increase in infertility cases globally for which many factors are responsible like increasing late marriages because of the career perspective. Age is an important factor in pregnancy as when the age of the woman increases, the chances of getting pregnant decreases. Increasing obesity and addiction of alcohol, tobacco and smoking are also the factors responsible for infertility.
Today, IVF accounts for 4% of the total birth in many European countries and is estimated to grow further. Many new techniques and treatments have been introduced in the market dealing with weak eggs, diminished ovarian reserve and the egg reserves which have shown positive results. Time lapse technology, frozen embryo transfer (FET) and intra cytoplasmic sperm injection (ICSI) are the technologies helping out in increasing the success rate of IVF. Japan occupies the largest share of the IVF cycles with Europe lying at the second position and the US at third. An increased focus on developing countries like India will affect the market where many of the infertile patients are not able to get the treatment because of unawareness or non-presence of the specialized doctors who can perform the therapy.
The key factors which are anticipated to drive IVF market includes increasing maternal age, decrease in global fertility, increased social acceptance of IVF, public financing, increase in global GDP and improvement in the healthcare expenses. Some of the significant developments of this industry are technological enhancement and innovation of techniques, increase in the medical tourism and increase in same sex marriage. However, the challenges to be faced are legal regulations, technical competence and cultural limitations, expensive therapy, side effects, risks like multiple births, ovarian hyper stimulation syndrome (OHSS), and stress, mental and emotional preparation.
This report offers a comprehensive analysis of the IVF market. Furthermore, market dynamics such as key trends and development; and challenges are analyzed in depth. On the contention front, the global IVF market is reined by few major players. The competitive landscape of the respective market, along with the company profiles of the leading players are also discussed in detail.
- 1. Market Overview
- 1.1 In Vitro Fertilization: An Introduction
- 1.2 Steps Involved in IVF and Embryo Transfer Process
- Table 1: Steps Involved in IVF and Embryo Transfer Process
- 1.3 Reasons for IVF Use
- Table 2: Breakdown of Male Infertility Causes (2015)
- Table 3: Breakdown of Female Infertility Causes (2015)
- Table A: Ways of Treatment of Infertility
- 1.4 Side Effects Associated with IVF
- 1.5 Risk Associated with IVF
- 1.6 Market Segmentation
- Table 4: Market Segments of IVF (2015)
- 2. Global IVF Market
- 2.1 Global IVF Market by Value
- Table 5: Global IVF Market by Value (2012-2014)
- 2.2 Global Annual IVF Cycles
- Table 6: Global Annual IVF Cycles (2014-2018E)
- 2.3 Global IVF Cycles by Region
- Table 7: IVF Cycles Share by Region (2014)
- 2.4 Global Fertility Rate by Regions
- Table 8: Global Fertility Rate by Region (2014)
- 2.5 Global Fertility Clinics Market Share by Region
- Table 9: Global Fertility Clinics Market Share by Region (2014)
- 2.6 Global IVF Treatment Cost by Region
- Table 10: Global IVF Treatment Cost by Region (2014)
- 2.7 Global Natural Conception by Age Group
- Table 11: Global Natural Conception by Age Group over a Year (2014)
- 2.8 Global Success Rate of IVF by Age Group
- Table 12: Global Success Rate of IVF by Age Group (2014)
- 2.9 Global Success Rate of IVF by Cycle
- Table 13: Global Success Rate of IVF by Cycle (2014)
- 3. Global IVF Market by Region
- 3.1 The US IVF Market
- 3.1.1 The US IVF Market by Value
- Table 14: The US IVF Market by Value (2014-2019E)
- 3.1.2 The US IVF Market by Share
- Table 15: The US IVF Market Share by Company (2014)
- 3.1.3 The US IVF Market by Cycles
- Table 16: The US IVF Market by Cycles (2014-2018E)
- 3.1.4 Infertility Rate by Age in the US
- Table 17: Infertility Rate by Age in the US (2014)
- 3.1.5 Same Sex Married Couples in the US
- Table 18: Same Sex Married Couples by Number (2008-2013)
- 3.1.6 Diagnosis Frequency for Infertility in the US
- Table 19: Diagnosis Frequency for Infertility in the US (2014)
- 3.1.7 Types of ART Cycles
- Table 20: Types of Assisted Reproductive Technology (ART) Cycles in the US (2014)
- 3.1.8 ART Use by Age Group
- Table 21: Assisted Reproductive Technology (ART) Use by Age Group in the US (2014)
- 3.1.9 ART – Outcome & Cancellations
- Table 22: Outcome of ART Cycles using Fresh Non Donor Eggs or Embryos (2013)
- Table 23: Reasons Cited for the Cancellation of ART (2014)
- 3.1.10 ART Cycle Resulted into Pregnancy
- Table 24: Percentage of Assisted Reproductive Technology (ART) Cycle that Resulted into Pregnancy (2014)
- Table 25: Percentage of Pregnancies Resulting in a Live Birth (2014)
- 3.2 Australia IVF Market
- 3.2.1 Australia IVF Market by Value
- Table 26: Australia IVF Market by Value (2011-2014)
- 3.2.2 Australia IVF Market Share by State
- Table 27: Australia IVF Market Share by State (2015)
- 3.2.3 Prominent Customer Age Group
- Table 28: Increase in the Prominent Customer Age Group (2006-2013)
- 3.3 India IVF Market
- 3.3.1 India IVF Market by Value
- Table 29: India IVF Market by Value (2012-2014)
- Table B: Current Scenario of Infertility Market in India (2015)
- Table C: Future Scenario of Infertility Market in India (2020E)
- 3.3.2 India IVF Cycles by Region
- Table 30: IVF Cycles Share by Region (2015)
- 3.3.3 India IVF Market Growth
- Table 31: Growth of IVF Market in India (2005/2015)
- Table 32: Patient Distribution by Sex (2015)
- Table 33: Patient Distribution by Income Level (2015)
- 3.3.4 ART Future Requirements in India
- 3.4 Europe IVF Market
- Table D: European IVF Market by Region (2015E)
- 3.4.1 European Union IVF Market by Cycles
- Table 34: European Union IVF Market by Cycles (2014-2018E)
- 4. Market Dynamics
- 4.1 Growth Drivers
- 4.1.1 Increasing Maternal age
- Table E: Decrease in Female Fertility with Age
- Table F: Decrease in Male Fertility with Age
- 4.1.2 Decrease in Global Fertility Rate
- Table 35: Global Fertility Rate (1965-2014)
- 4.1.3 Increased Social Acceptance of IVF
- 4.1.4 Public Financing
- 4.1.5 Increase in Global GDP
- Table 36: Global GDP Growth (2006-2014)
- 4.1.6 Improvement in Global Healthcare Expenditure
- Table 37: Global Healthcare Expenditure (2007-2014)
- 4.1.7 Increase in the Obese Population
- Table 38: Global Obese Population (2006-2014)
- 4.2 Trends and Development
- 4.2.1 Technological Enhancement and Innovation of Techniques
- PGD (Preimplantation Genetic Diagnosis)
- PGS (Preimplantation Genetic Screening)
- Time Lapse Technology
- ICSI (Intracytoplasmic Sperm Injection)
- 4.2.2 Increase in Medical Tourism
- Table 39: Medical Tourism Industry
- Table G: Reasons for Seeking Infertility Treatment
- 4.2.3 Increase in LGBT Marriages
- 4.3 Challenges
- 4.3.1 Legal Regulations
- Table H: Legal Regulations Regarding Eligibility Criteria for IVF in Some Countries
- 4.3.2 Technical Incompetence and Cultural Limitations
- 4.3.3 Expensive Therapy and Side Affects
- 4.3.4 Mental and Emotional Preparation
- 5. Competitive Landscape
- Table I: OVAS Key Products
- Table J: Comparison of Innovative Products with the Ongoing Development
- Table K: Comparative Analysis between Ova Sciences, Vitrolife and Monash (2014)
- 6. Company Profiles
- 6.1 Vitrolife
- 6.1.1 Business Overview
- Table 40: Vitrolife Sales by Region (2014/2013)
- Table 41: Average Number of Employees (2010-2014)
- 6.1.2 Financial Overview
- Table 42: Vitrolife Revenue and Net Income (2010-2014)
- 6.1.3 Business Strategies
- 6.2 Monash
- 6.2.1 Business Overview
- Table 43: Number of Patients Treated Related to IVF (2011-2014)
- Table 44: Number of IVF Cycles (2013-2014)
- Table 45: Number of Frozen Embryo Transfers (2013-2014)
- 6.2.2 Financial Overview
- Table 46: Monash Revenue (2010-2014)
- 6.2.3 Business Strategies
- 6.3 Ova Sciences
- 6.3.1 Business Overview
- Table 47: Estimated Sales of AUGMENT (2017E-2030E)
- Table 48: Estimated Sales of OvaPrime (2017E-2030E)
- 6.3.2 Financial Overview
- Table 49: Ova Sciences R&D Expenses and Net Loss (2012-2015)
- 6.3.3 Business Strategies